---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006999"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:30:59.602710+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reports Q4 net loss $30.7M; cash $282.9M; clinical milestones ahead

## Summary
- Q4 2022 GAAP net loss $30.7M ($0.75/sh) vs $28.4M ($0.70/sh) in Q4 2021.
- Full year 2022 GAAP net loss $123.5M ($3.03/sh) vs $83.5M ($2.07/sh) in 2021.
- Cash & investments $282.9M; $100M loan facility (drew $10M); runway through mid-2025.
- Key milestones: ASPEN-06 (gastric) and ASPEN-02 (MDS) data H2 2023; ASPEN-07 (UC) dosed Feb 2023.
- Board strengthened with Scott Garland; IND for ALTA-002 (Tallac) expected H1 2023.

## SEC filing metadata
- accession: 0000950170-23-006999
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/0000950170-23-006999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/alxo-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006999
- JSON: https://secwatch.observer/filing/0000950170-23-006999.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006999.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/0000950170-23-006999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.